| Literature DB >> 31175826 |
Eudocia Q Lee1,2, Ugonma N Chukwueke1,2, Shawn L Hervey-Jumper3, John F de Groot4, Jose Pablo Leone1,2, Terri S Armstrong5, Susan M Chang3, David Arons6, Kathy Oliver7, Kay Verble8, Al Musella9, Nicole Willmarth10, Brian M Alexander11, Amanda Bates6, Lisa Doherty6, Evanthia Galanis12, Sarah Gaffey1, Thomas Halkin1, Bret E Friday13, Maryam Fouladi14, Nancy U Lin1, David Macdonald15, Minesh P Mehta16, Marta Penas-Prado5, Michael A Vogelbaum17, Solmaz Sahebjam17, David Sandak18, Martin van den Bent19, Michael Weller20, David A Reardon1, Patrick Y Wen1.
Abstract
Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.Entities:
Keywords: brain tumors; clinical trial accrual; neuro-oncology
Mesh：
Year: 2019 PMID： 31175826 PMCID： PMC7594546 DOI： 10.1093/neuonc/noz104
Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300